Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure

Phase 4

Completed

• Conditions: Chronic Heart Failure
• Interventions: Drug: acetazolamide

• Registration Number: NCT00517426
• Lead Sponsor: Centro Cardiologico Monzino

Brief Summary

To evaluate the effects of CO2 inhalation and acetazolamide treatment on exercise-induced periodic breathing in patients with chronic stable heart failure.

Patients will be given CO2 (2%) during a constant workload exercise. Patients will be also evaluated by maximal cardiopulmonary exercise test without and with acetazolamide acute and chronic treatment.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2007-08-16
• Study First Submitted QC: 2007-08-16
• Study First Posted: 2007-08-17
• Primary Completion: 2011-07
• Study Completion: 2012-08
• Status Verified: 2016-01
• Last Update Submitted: 2016-01-27
• Last Update Posted: 2016-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• chronic heart failure in stable clinical condition
• exercise-induced periodic breathing

Exclusion Criteria

• comorbidities
• NYHA class IV

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Active Acetazolamide	acetazolamide	-

Primary Outcome Measures

Name	Time	Method
Suppression of periodic breathing	two days

Secondary Outcome Measures

Name	Time	Method
suppression of sleeping apnea	two days

Trial Locations

Locations (1)

Centro Cardiologico Monzino, University of Milan; 🇮🇹 Milan, Italy